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Abstract MacB is an ABC-type membrane protein that ex-
ports only macrolide compounds containing 14- and 15-mem-
bered lactones, cooperating with a membrane fusion protein,
MacA, and a multifunctional outer membrane channel, TolC.
We determined the membrane topology of MacB by means of
site-speci¢c competitive chemical modi¢cation of single cysteine
mutants. As a result, it was revealed that MacB is composed of
four transmembrane (TM) segments with a cytoplasmic N-ter-
minal nucleotide binding domain of about 270 amino acid resi-
dues and a periplasmic large hydrophilic polypeptide between
TM segments 1 and 2 of about 200 amino acid residues.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Although drug resistance mediated by active drug e¥ux is
mainly due to ATP binding cassette (ABC) transporters such
as P-glycoprotein and MRP [1] in eukaryotes, no drug-export-
ing ABC transporters are known in bacteria except for LmrA
in Lactococcus lactis [2] and its homolog [3], while many ABC
transporters exist. We previously reported that MacB is a
macrolide antibiotic-speci¢c drug exporter in Escherichia
coli, which was the ¢rst ABC-type drug exporter experimen-
tally identi¢ed in a Gram-negative bacterium [4]. MacB ex-
ports macrolide compounds containing 14- and 15-membered
lactones. It requires a membrane fusion protein (MFP) [5],
MacA, and a multifunctional outer membrane channel pro-
tein, TolC, for its function [4].
MacB is a half-type ABC transporter having only one nu-
cleotide binding domain (NBD). Although in most half-type
ABC transporters the NBD domain is at the C-terminus, in
MacB it is at the N-terminus, similar to in the ABCG sub-
family [6], while MacB shows no sequence homology to any
ABCG family proteins. In addition, judging from the results
of amino acid sequence analysis, MacB comprises only four
transmembrane (TM) segments [4]. The number of predicted
TM segments of MacB is minimum in half-type ABC trans-
porters, most of which comprise six TM segments [7].
In this study we try to determine the precise number of TM
segments of MacB on the basis of the experimental results of
competitive site-directed chemical modi¢cation. This method
has been proved to be the most reliable one for topology
determination of a membrane protein [8^10]. This method is
based on the fact that the binding of a membrane-permeable
SH reagent, NEM (N-ethyl maleimide), to a cysteine residue
located on the outside surface of the membrane is prevented
by a membrane-impermeable SH reagent, AMS (4-aceto-
amide-4P-maleimidylstilbene-2,2P-disulfonic acid), while the
binding of NEM to a cysteine residue located on the inside
surface of the membrane is not a¡ected by AMS when intact
cells are incubated with NEM and AMS [9,10].
On the basis of the results of competitive site-directed
chemical modi¢cation of 33 Cys mutants with NEM and
AMS, we determined that the MacB polypeptide chain spans
the membrane four times, and that its N-terminal NBD
(about 260 amino acids) and the large polypeptide loop
(about 200 amino acids) between TM1 and TM2 are actually
located on the cytoplasmic and periplasmic sides of the mem-
brane, respectively.
2. Materials and methods
2.1. Bacterial strains and plasmids
E. coli strains W3104 [11], CJ236 [12], and JM109 [13] were used for
gene disruption, single-stranded DNA preparation, and plasmid con-
struction, respectively. Plasmids pBAD24 and pBAD33 were de-
scribed previously [14] and obtained from the National Institute of
Genetics (Mishima, Japan). Plasmid pUC118 (Takara Shuzo Co.) was
obtained from a commercial source. Plasmid pKO3 was a gift from
George M. Church [15]. Plasmids pBAD24 [14] and pBAD33 [14] are
arabinose-induced expression vectors that contain the PBAD promoter
and araC gene. Plasmid pBAD24 contains ampr and the pBR322
origin of replication. Plasmid pBAD33 contains Cmr and the pA-
CYC184 origin of replication. Plasmid pKO3 is a gene replacement
vector that contains a temperature-sensitive origin of replication, and
markers for positive and negative selection for chromosomal integra-
tion and excision.
2.2. Materials
N-[Ethyl-1-14C] maleimide (1.5 GBq/mmol) was purchased from
Perkin-Elmer Life Sciences. AMS was purchased from Molecular
Probes. All other materials were of reagent grade and obtained
from commercial sources.
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2.3. Gene disruption
Deletions of the chromosomal macAB and acrAB genes were cre-
ated by in-frame crossover polymerase chain reaction (PCR) [15], and
then the deletions were placed in the E. coli chromosome by means of
plasmid pKO3. The resulting strain was named E. coli W3104va-
crABvmacAB. Gene deletions were con¢rmed by the lengths of the
PCR fragments of the chromosomal acrAB and macAB genes.
2.4. Mutagenesis
First of all, ¢ve new silent restriction sites (SacI, KpnI, BglII, XbaI
and SpeI) and a 3P-terminal poly-histidine tag were introduced into
the macB gene, and the resulting cassetted macB gene was cloned into
the NcoI^SalI sites of pBAD24. The resulting plasmid, pB2BKN (Fig.
1A), was used for MacB expression. In order to construct Cys-intro-
duced mutants, the macB gene was cloned into pUC118 and the
resulting pUC8macBKUNKEL was used for site-directed mutagenesis
by the method of Kunkel [12] as a template. The mutation site was
replaced in pB2BKN by means of restriction enzyme^cassette ex-
change. Plasmid pB3A (Fig. 1B) carrying the macA gene was con-
structed by cloning of the macA gene into pBAD33. E. coli W3104va-
crABvmacAB was co-transformed by pB3A and pB2BKN or one of
its mutational derivatives.
2.5. Drug resistance assays
The resistance of cells harboring the indicated plasmids with macA
and macB constructs under the control of the arabinose promoter was
measured by the agar dilution method [16] with the indicated concen-
trations of arabinose.
2.6. Prevention of NEM binding with AMS
The experiment was performed as previously reported [10]. Without
any exceptions, W3104vacrABvmacAB harboring mutant plasmids
was grown in minimal medium supplemented with 0.1% casamino
acids and 0.4% glycerol. In the middle of the logarithmic phase,
macB gene expression was induced with 0.2% (w/v) arabinose for
2 h, followed by solubilization with 2% Triton X-100 in place of 1%
Triton X-100 and 0.1% sodium dodecyl sulfate (SDS).
3. Results
3.1. Construction and expression of Cys mutants of MacB in
acrAB and macAB double-knockout E. coli cells
We ¢rst removed the acrAB gene from the E. coli W3104
Table 1
Erythromycin resistance, MacB expression and NEM binding of E. coli cells harboring multicopy plasmids encoding Cys mutant macB gene
and plasmid pB3A encoding wild-type macA gene
Strain Plasmid 1 Plasmid 2 MIC (Wg/ml)/arabinose (%) MacB expression NEM binding
0.2 2
W3104 No No 200 200 slight N.D.a
W3104vacrAB No No 6.25 6.25 slight N.D.
W3104vacrABvmacAB No No 3.13 3.13 mp N.D.
pB2ABNH No 25 50 yes no
pB2BKN No 3.13 3.13 yes no
pB3A No 3.13 3.13 no N.D.
pB2 C56A pB3A 12.5 50 yes no
pB2 S13C pB3A 3.13 3.13 no N.D.
pB2 Y14C pB3A 6.25 25 yes yes
pB2S28C pB3A 12.5 50 yes yes
pB2 S62C pB3A 12.5 50 yes yes
pB2 L98C pB3A 12.5 50 yes yes
pB2 L128C pB3 12.5 50 yes yes
pB2 Q151C pB3A 12.5 50 yes no
pB2 G173C pB3A 6.25 12.5 yes yes
pB2 I198C pB3A 12.5 50 yes no
pB2 A207C pB3A 3.13 3.13 no N.D.
pB2 A227C pB3A 12.5 50 yes yes
pB2 S252C pB3A 12.5 25 yes yes
pB2 A261C pB3A 3.13 3.13 no N.D.
pB2 A267C pB3A 12.5 50 yes yes
pB2 S306C pB3A 6.25 12.5 yes yes
pB2 Y327C pB3A 12.5 50 yes yes
pB2 A347C pB3A 12.5 50 yes yes
pB2 T383C pB3A 25 50 yes yes
pB2 L412C pB3A 25 50 yes no
pB2 A417C pB3A 25 50 yes yes
pB2 S442C pB3A 3.13 3.13 yes yes
pB2 F444C pB3A 3.13 3.13 yes yes
pB2 S446C pB3A 3.13 3.13 no N.D.
pB2 S467C pB3A 12.5 50 yes yes
pB2 S494C pB3A 12.5 50 yes yes
pB2 T517C pB3A 12.5 25 yes yes
pB2 T520C pB3A 12.5 25 yes no
pB2 T523C pB3A 25 50 yes no
pB2 T552C pB3A 12.5 50 yes yes
pB2 V561C pB3A 12.5 50 yes no
pB2 S566C pB3A 12.5 50 yes yes
pB2 L602C pB3A 12.5 50 yes yes
pB2 G604C pB3A 25 100 yes yes
pB2 A633C pB3A 12.5 25 yes no
pB2 A637C pB3A 12.5 50 yes no
pB2 D643C pB3A 12.5 50 yes yes
pB2 A646C pB3A 12.5 50 yes yes
The resistance levels were depicted as minimum inhibitory concentration (Wg/ml) determined by the agar dilution method.
aN.D., not done.
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chromosome as described in Section 2, since constitutively
expressed AcrAB masks the macrolide resistance phenotype
of MacB [17,18]. Then, the macAB gene was removed from E.
coli W3104vacrAB. The resulting double-knockout strain,
W3104vacrABvmacAB, was used as the host for the expres-
sion of Cys mutant MacB. The minimum inhibitory concen-
trations of erythromycin for E. coli cells are listed in Table 1.
E. coli W3104vacrAB was 32-fold more sensitive to erythro-
mycin than wild-type W3104. W3104vacrABvmacAB was
two-fold more sensitive to erythromycin than W3104vacrAB.
The contribution of the chromosomal macAB gene to eryth-
romycin resistance appears to be less than that of the acrAB
gene, probably because the expression of MacAB from the
chromosome under normal conditions is less than that of
AcrAB.
MacB has three intrinsic Cys residues, that is, Cys56,
Cys580 and Cys620. Among them, Cys56 is located in the
¢rst putative loop region, and Cys580 and Cys620 in the pu-
tative TM region. First of all, we replaced Cys56 with Ala.
The resulting C56A mutant showed no reactivity with NEM
(Fig. 2), indicating that Cys580 and Cys620 are embedded in
the hydrophobic region of the membrane. Thus, we used the
C56A mutant to introduce a new Cys residue by site-directed
mutagenesis. We constructed 37 Cys mutants in which a single
Cys residue was introduced at 30^40 amino acid intervals.
Since MacB requires MFP MacA for its function, E. coli
Fig. 1. Plasmid maps of pB2BKN and pB3A. Numbers given with the restriction enzyme sites are positions from the macB start codon. Abbre-
viation: ori, origin of replication.
Fig. 2. The expression of single cysteine mutants of MacB and the e¡ect of AMS on [14C]NEM binding to these mutants. E. coli cells carrying
MacB proteins were incubated in the presence (+) or absence (3) of 5 mM AMS, and then incubated with 0.5 mM NEM containing 62.5 WM
[14C]NEM. Cells were disrupted by sonication. After membrane fractions had been collected by ultracentrifugation, the MacB proteins were
solubilized with 2% Triton X-100 (v/v) and then puri¢ed on Ni-chelating Sepharose (Amersham Pharmacia Biotech.). The puri¢ed MacB pro-
teins were subjected to SDS^PAGE. The protein bands (upper panel) and radioactive bands (lower panel) were visualized by Coomassie bril-
liant blue staining and autoradiography with a BAS-1000 Bioimaging analyzer, respectively.
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Fig. 3. Membrane topology of MacB determined in this study and the locations of the introduced cysteines. Cys56, which was replaced by Ala,
and the other two intrinsic cysteines are depicted as bold letters. Blue ovals, NEM labeling was completely or largely blocked by AMS; red
ovals, labeling was not a¡ected by pretreatment with AMS; open circles, [14C]NEM was not reacted regardless of pretreatment or not with
AMS; pink squares, nucleotide binding motifs. Yellow squares indicate the most probable membrane-spanning domain determined with SOSUI
[27].
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W3104vacrABvmacAB was co-transformed with a plasmid
carrying a Cys mutant macB gene and pB3A that carries a
macA gene. Both the macB and macA genes are under the
control of the arabinose promoter. Among the 37 Cys mu-
tants, only six (S13C, A207C, A261C, S442C, F444C and
S446C) had lost the ability to confer erythromycin resistance
to W3104vacrABvmacAB (Table 1).
Four (S13C, A207C, A261C and S446C) of them showed
no MacB expression at all, while the other two (S442C and
F444C) expressed MacB proteins (Table 1 and Fig. 2). Ser442
and Phe444 might be essential for the MacB function. The 33
MacB-expressing mutants including S442C and F444C were
used for topology determination.
3.2. Prevention of [14C]NEM binding to the Cys mutants of
MacB by AMS in intact cells
E. coli W3104vacrABvmacAB cells expressing mutant
MacB proteins were pre-incubated in the absence or presence
of 5 mM AMS, and then treated with 0.5 mM NEM contain-
ing 62.5 WM [14C]NEM, as described in Section 2. Seven mu-
tants (Q151C, I198C, L412C, L523C, V561C, A633C and
A637C) were not labeled at all by NEM regardless of the
presence or absence of AMS (Table 1 and Fig. 2), indicating
that these residues might be embedded in the hydrophobic
region of the membrane or the interior of the protein. The
NEM binding to the 13 mutants (Y14C, S28C, S62C, L98C,
L128C, G173C, A227C, S252C, A267C, T552C, S566C,
D643C and A646C) was not a¡ected by pretreatment with
AMS at all, indicating that these residues are located on the
cytoplasmic surface of the membrane. The binding of NEM to
the other 13 mutants (S306C, Y327C, S347C, T383C, A417C,
S442C, F444C, S467C, S494C, T517C, T520C, L602C and
G604C) was signi¢cantly inhibited by pretreatment with
AMS, indicating that these residues are located on the outside
surface of the membrane.
Fig. 3 summarizes the results as to the putative MacB to-
pology. Viewed from the N-terminus, the NEM binding to the
eight NEM-reactive Cys mutants (Y14C, S62C, L98C, L128C,
G173C, A227C, S252C and A267C) was not a¡ected by AMS
and thus these residues are inside. In order to span the mem-
brane once as an K-helical form, a polypeptide chain of about
20 amino acid residues in length is required. The intervals of
the introduced Cys residues were planned to be less than 40
amino acid residues in order to exclude the possibility of
spanning twice between them. Although the length of the
continuous spans between Leu128 and Gly173, and Gly173
and Ala227 was longer than 40 amino acid residues, it is
not likely that any residue between the N-terminus to
Ala267 is located on the opposite surface of the membrane,
since the former span contains the Walker motif and ABC
signature sequence, and the latter one contains the essential
switching histidine residue (His195 or His202) in NBD. There-
fore, the N-terminus containing NBD is concluded to be in-
side. Between Ala267 and Ser306, the localization changed
from inside to outside. There are only 39 residues between
them, indicating the presence of one TM K-helix. Between
Ser306 and Thr520, all NEM-reactive mutations were local-
ized outside. For the reason stated above, there may be no
TM segments between them, and the polypeptide chain be-
tween Ser306 and Thr520 must be a large periplasmic loop.
Three more TM segments exist between Thr520 and Thr552,
Ser566 and Leu602, and Gly604 and Asp643. In conclusion,
MacB contains four TM K-helices, one cytoplasmic NBD do-
main and one large periplasmic loop.
4. Discussion
In this study, we showed that MacB has four TM segments
with one N-terminal NBD domain and a periplasmic large
loop. With respect to the number of NBD domains, MacB
is a half-type ABC transporter like LmrA, which functions as
a dimer [19]. However, the number of TM segments is less
than that of normal half-type ABC transporters, which in
general comprise six TM segments [7]. To the best of our
knowledge, the LolC and LolE proteins are amongst the
few examples of ABC proteins that have four putative TM
segments [20]. However, they are not transporters but proteins
mediating lipoprotein release from the cytoplasmic membrane
surface in E. coli [20].
Drug transporters having the smallest number of TM seg-
ments hitherto reported are small multidrug resistance (SMR)
family transporters such as EmrE [21,22] in bacteria. They
have been predicted to have four TM segments [22]. Thus,
MacB has the smallest number of TM segments among solute
transporters, similar to SMR family transporters [23]. SMR-
type transporters are estimated to each function as a dimer of
dimers. Thus, the functional unit of SMR family transporters
comprises 16 TM segments.
An important feature of MacB is the cooperation with
TolC for drug e¥ux. Recently, we reported the crystal struc-
ture of multidrug e¥ux transporter AcrB [24] that exports a
wide variety of toxic compounds, which is driven by proton
motive force, in cooperation with TolC and MFP [10]. Ac-
cording to its crystal structure, AcrB is a trimer. Each mono-
mer has two large periplasmic loops between TM1 and TM2,
and TM7 and TM8. Thus, the large periplasmic domain of
the AcrB trimer comprises six hydrophilic polypeptide loops,
which are presumed to dock with the TolC trimer. If MacB
acts as a hexamer, it also has six periplasmic loops and three
NBD pairs. This assumption is reasonable for TolC docking
and ATP hydrolysis.
MefA and MefE are well-characterized antiporter-type
macrolide e¥ux transporters energized by proton motive force
[25,26]. Interestingly, MacB shows a similar substrate speci¢c-
ity to Mef family transporters. Mef family exporters can
transport 14- and 15-membered macrolides but not 16-mem-
bered ones, similar to MacB. Although the driving force for
MacB is di¡erent from that for Mef transporters, their sub-
strate recognition site(s) might be similar, while the amino
acid sequences of these transporters exhibit almost no similar-
ity. In any case, comparison of the substrate binding sites of
MacB, AcrB and Mef family transporters should be a very
interesting subject for future study.
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